240 related articles for article (PubMed ID: 25273821)
1. Confirmation of genetic variants associated with lethal prostate cancer in a cohort of men from hereditary prostate cancer families.
Karyadi DM; Zhao S; He Q; McIntosh L; Wright JL; Ostrander EA; Feng Z; Stanford JL
Int J Cancer; 2015 May; 136(9):2166-71. PubMed ID: 25273821
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
Shui IM; Lindström S; Kibel AS; Berndt SI; Campa D; Gerke T; Penney KL; Albanes D; Berg C; Bueno-de-Mesquita HB; Chanock S; Crawford ED; Diver WR; Gapstur SM; Gaziano JM; Giles GG; Henderson B; Hoover R; Johansson M; Le Marchand L; Ma J; Navarro C; Overvad K; Schumacher FR; Severi G; Siddiq A; Stampfer M; Stevens VL; Travis RC; Trichopoulos D; Vineis P; Mucci LA; Yeager M; Giovannucci E; Kraft P
Eur Urol; 2014 Jun; 65(6):1069-75. PubMed ID: 24411283
[TBL] [Abstract][Full Text] [Related]
3. Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases.
FitzGerald LM; Zhao S; Leonardson A; Geybels MS; Kolb S; Lin DW; Wright JL; Eeles R; Kote-Jarai Z; Govindasami K; Giles GG; Southey MC; Schleutker J; Tammela TL; Sipeky C; Penney KL; Stampfer MJ; Gronberg H; Wiklund F; Stattin P; Hugosson J; Karyadi DM; Ostrander EA; Feng Z; Stanford JL
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):228-237. PubMed ID: 29298992
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.
Lin DW; FitzGerald LM; Fu R; Kwon EM; Zheng SL; Kolb S; Wiklund F; Stattin P; Isaacs WB; Xu J; Ostrander EA; Feng Z; Grönberg H; Stanford JL
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1928-36. PubMed ID: 21846818
[TBL] [Abstract][Full Text] [Related]
5. Association of six susceptibility Loci with prostate cancer in northern chinese men.
Zhang YR; Xu Y; Yang K; Liu M; Wei D; Zhang YG; Shi XH; Wang JY; Yang F; Wang X; Liang SY; Zhao CX; Wang F; Chen X; Sun L; Zhu XQ; Zhu L; Yang YG; Tang L; Jiao HY; Huo ZH; Yang Z
Asian Pac J Cancer Prev; 2012; 13(12):6273-6. PubMed ID: 23464444
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients.
Sun J; Lange EM; Isaacs SD; Liu W; Wiley KE; Lange L; Gronberg H; Duggan D; Carpten JD; Walsh PC; Xu J; Chang BL; Isaacs WB; Zheng SL
Prostate; 2008 Apr; 68(5):489-97. PubMed ID: 18213635
[TBL] [Abstract][Full Text] [Related]
7. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.
Seibert TM; Fan CC; Wang Y; Zuber V; Karunamuni R; Parsons JK; Eeles RA; Easton DF; Kote-Jarai Z; Al Olama AA; Garcia SB; Muir K; Grönberg H; Wiklund F; Aly M; Schleutker J; Sipeky C; Tammela TL; Nordestgaard BG; Nielsen SF; Weischer M; Bisbjerg R; Røder MA; Iversen P; Key TJ; Travis RC; Neal DE; Donovan JL; Hamdy FC; Pharoah P; Pashayan N; Khaw KT; Maier C; Vogel W; Luedeke M; Herkommer K; Kibel AS; Cybulski C; Wokolorczyk D; Kluzniak W; Cannon-Albright L; Brenner H; Cuk K; Saum KU; Park JY; Sellers TA; Slavov C; Kaneva R; Mitev V; Batra J; Clements JA; Spurdle A; Teixeira MR; Paulo P; Maia S; Pandha H; Michael A; Kierzek A; Karow DS; Mills IG; Andreassen OA; Dale AM;
BMJ; 2018 Jan; 360():j5757. PubMed ID: 29321194
[TBL] [Abstract][Full Text] [Related]
8. Endothelial nitric oxide synthase gene polymorphisms and prostate cancer risk in Serbian population.
Branković A; Brajušković G; Nikolić Z; Vukotić V; Cerović S; Savić-Pavićević D; Romac S
Int J Exp Pathol; 2013 Dec; 94(6):355-61. PubMed ID: 23998439
[TBL] [Abstract][Full Text] [Related]
9. Single-nucleotide polymorphisms in DNMT3B gene and DNMT3B mRNA expression in association with prostate cancer mortality.
Zelic R; Fiano V; Ebot EM; Coseo Markt S; Grasso C; Trevisan M; De Marco L; Delsedime L; Zugna D; Mucci LA; Richiardi L
Prostate Cancer Prostatic Dis; 2019 May; 22(2):284-291. PubMed ID: 30341411
[TBL] [Abstract][Full Text] [Related]
10. CYP17 polymorphisms and prostate cancer outcomes.
Wright JL; Kwon EM; Lin DW; Kolb S; Koopmeiners JS; Feng Z; Ostrander EA; Stanford JL
Prostate; 2010 Jul; 70(10):1094-101. PubMed ID: 20503394
[TBL] [Abstract][Full Text] [Related]
11. Variation in selenoenzyme genes and prostate cancer risk and survival.
Geybels MS; Hutter CM; Kwon EM; Ostrander EA; Fu R; Feng Z; Stanford JL; Peters U
Prostate; 2013 May; 73(7):734-42. PubMed ID: 23143801
[TBL] [Abstract][Full Text] [Related]
12. Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG).
Jin G; Lu L; Cooney KA; Ray AM; Zuhlke KA; Lange EM; Cannon-Albright LA; Camp NJ; Teerlink CC; Fitzgerald LM; Stanford JL; Wiley KE; Isaacs SD; Walsh PC; Foulkes WD; Giles GG; Hopper JL; Severi G; Eeles R; Easton D; Kote-Jarai Z; Guy M; Rinckleb A; Maier C; Vogel W; Cancel-Tassin G; Egrot C; Cussenot O; Thibodeau SN; McDonnell SK; Schaid DJ; Wiklund F; Grönberg H; Emanuelsson M; Whittemore AS; Oakley-Girvan I; Hsieh CL; Wahlfors T; Tammela T; Schleutker J; Catalona WJ; Zheng SL; Ostrander EA; Isaacs WB; Xu J;
Hum Genet; 2012 Jul; 131(7):1095-103. PubMed ID: 22198737
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of five genetic variants for predicting prostate cancer risk and mortality.
Salinas CA; Koopmeiners JS; Kwon EM; FitzGerald L; Lin DW; Ostrander EA; Feng Z; Stanford JL
Prostate; 2009 Mar; 69(4):363-72. PubMed ID: 19058137
[TBL] [Abstract][Full Text] [Related]
14. Replication of a genetic variant for prostate cancer-specific mortality.
Penney KL; Shui IM; Feng Z; Sesso HD; Stampfer MJ; Stanford JL
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):260-3. PubMed ID: 25939514
[TBL] [Abstract][Full Text] [Related]
15. Association of 8 loci on chromosome 8q24 with prostate carcinoma risk in northern Chinese men.
Zhao CX; Liu M; Wang JY; Xu Y; Wei D; Yang K; Yang Z
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6733-8. PubMed ID: 24377597
[TBL] [Abstract][Full Text] [Related]
16. DNA repair gene X-ray repair cross-complementing group 1 and xeroderma pigmentosum group D polymorphisms and risk of prostate cancer: a study from North India.
Mandal RK; Gangwar R; Mandhani A; Mittal RD
DNA Cell Biol; 2010 Apr; 29(4):183-90. PubMed ID: 20070155
[TBL] [Abstract][Full Text] [Related]
17. Association of Hsa-miR-23a rs3745453 variation with prostate cancer risk among Chinese Han population: A case-control study.
Zhang M; Wang Y; Wang C; You Z; Chen S; Kong Q; Xu B; Liu C; Chen M
Medicine (Baltimore); 2019 Dec; 98(52):e18523. PubMed ID: 31876746
[TBL] [Abstract][Full Text] [Related]
18. Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.
Gu C; Li Q; Zhu Y; Qu Y; Zhang G; Wang M; Yang Y; Wang J; Jin L; Wei Q; Ye D
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):310-6. PubMed ID: 26238235
[TBL] [Abstract][Full Text] [Related]
19. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
Kader AK; Sun J; Isaacs SD; Wiley KE; Yan G; Kim ST; Fedor H; DeMarzo AM; Epstein JI; Walsh PC; Partin AW; Trock B; Zheng SL; Xu J; Isaacs W
Prostate; 2009 Aug; 69(11):1195-205. PubMed ID: 19434657
[TBL] [Abstract][Full Text] [Related]
20. Genetic risk assessment of lethal prostate cancer using polygenic risk score and hereditary cancer susceptibility genes.
Ruan X; Huang D; Huang J; Tsu JH; Na R
J Transl Med; 2023 Jul; 21(1):446. PubMed ID: 37415201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
